山東新華製藥股份(00719.HK)擬向華魯投資增發3628.45萬股A股 籌資2.5億元
格隆匯 4 月 14日丨山東新華製藥股份(00719.HK)公佈,於2021年4月14日,董事會宣佈批准建議非公開發行A股,並且公司與華魯投資訂立A股認購協議,據此,公司將向華魯投資發行3628.45萬股A股(佔現有已發行股份總數的約5.78%),現金髮行價為A股每股人民幣6.89元。預期募集資金總額(扣除開支前)為人民幣2.50億元。
根據建議A股發行擬發行的A股數目為3628.45萬股,相當於(i)於公吿日期,現有已發行A股數目的約8.39%及於公吿日期,現有已發行股份總數的約5.78%;及(ii)於建議A股發行完成後,已發行A股數目的約7.74%及已發行股份總數的約5.47%,各情況下均指經擬發行A股數目擴大後的股份。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.